Welcome to our dedicated page for Pharming Group N.V. SEC filings (Ticker: PHAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharming Group N.V. SEC filings document a foreign private issuer commercializing rare-disease medicines and reporting through Form 6-K current reports and Form 20-F annual disclosures. The filings cover financial results, revenue trends for RUCONEST® and Joenja® (leniolisib), regulatory developments for APDS, and clinical-program disclosures involving primary immunodeficiencies with immune dysregulation and napazimone (KL1333) in primary mitochondrial disease.
The company's regulatory record also includes annual-report filings, shareholder-meeting materials, auditor appointment matters, remuneration policy proposals, and authorizations related to share issuance and repurchases. These disclosures frame Pharming's governance, capital structure, commercial products, pipeline spending, licensing obligations, and rare-disease development risks.
Pharming Group N.V. reports that Japan’s Ministry of Health, Labour and Welfare has approved Joenja (leniolisib) for activated PI3K delta syndrome (APDS) in adults and children aged 4 years and older. Joenja becomes the first treatment approved in Japan specifically for APDS and the first worldwide to cover children aged 4 to 11 with the disease.
The approval is based on positive Phase III data from multinational and Japanese studies in patients 12 years and older and a multinational pediatric study in children 4 to 11 years, showing reduced lymphadenopathy and increased naïve B cells. Under an agreement with Pharming, OrphanPacific serves as Marketing Authorization Holder in Japan and will handle supply and distribution. Launch is expected after agreement on National Health Insurance drug pricing. Joenja is already approved for APDS patients 12 and older in the U.S., U.K., Australia and Israel.
Pharming Group N.V. reports preliminary 2025 results with total revenues of US$376.1 million, up 27% from 2024, driven by growth in RUCONEST® and Joenja®.
The company swung from an operating loss of US$8.6 million to an operating profit of US$25.8 million, and from a net loss of US$11.8 million to a net profit of US$2.5 million. Net cash flow from operations was US$54.7 million, lifting total cash, restricted cash and marketable securities to US$181.1 million at year-end.
RUCONEST® full-year revenue rose 26% to US$317.9 million, while Joenja® revenue increased 29% to US$58.2 million, supported by a 25% rise in U.S. patients on paid therapy. For 2026, Pharming guides to total revenues of US$405–425 million (8–13% growth) and higher operating expenses as it advances leniolisib and napazimone (KL1333). Regulatory progress includes expected decisions on leniolisib in the EU, Japan and Canada, although the FDA issued a Complete Response Letter for the U.S. pediatric sNDA requiring additional data.
Pharming Group N.V. issued 2026 financial guidance and highlighted its rare disease pipeline at a virtual Investor Day. The company expects total revenues between US$405 million and US$425 million, implying 8% to 13% growth, driven by Joenja and continued contribution from RUCONEST.
Total operating expenses are guided to US$330 million to US$335 million, mainly reflecting higher research and development spending for ongoing Phase II trials of leniolisib and the pivotal FALCON trial of napazimone (KL1333). Management presented leniolisib’s expansion into broader primary immunodeficiency and CVID populations, with top-line Phase II data expected in the second half of 2026, and confirmed that the napazimone FALCON trial for mtDNA‑driven mitochondrial disease remains on track for a 2027 readout.
Pharming Group N.V. reports that the U.S. FDA has issued a Complete Response Letter to its supplemental New Drug Application for Joenja (leniolisib) in children aged 4 to 11 years with APDS, a rare primary immunodeficiency.
The FDA is concerned about potential underexposure in lower weight pediatric patients and has requested additional pharmacokinetic data to reassess dosing, along with clarification on an analytical method used in production batch testing. Pharming plans to request a Type A meeting and work with the FDA on resubmission. Joenja’s existing U.S. approval for APDS in patients 12 years and older remains unchanged.
Pharming Group N.V. reported preliminary, unaudited full-year 2025 revenues of approximately US$376 million, above its upwardly revised guidance range of US$365–375 million and about 27% growth versus 2024. Management attributes this performance to continued growth of RUCONEST® and strong uptake of Joenja®, especially from U.S. patients and broader geographic expansion. Full-year 2025 operating expenses are expected to land within the previously communicated range of US$304–308 million, reflecting cost discipline.
The company plans to host a virtual Investor Day on February 3, 2026, where it will give pipeline updates on leniolisib in Phase II proof-of-concept trials for primary immunodeficiencies, including CVID with immune dysregulation, and on KL1333 in the pivotal FALCON study for mtDNA-driven mitochondrial disease. Pharming also intends to present its 2026 financial guidance and report full fourth quarter and full-year 2025 results on March 12, 2026.
Pharming Group N.V. reported a strong third quarter, with total revenue of US$97.3 million, up 30% year over year. RUCONEST® delivered US$82.2 million (up 29%) on higher U.S. volume, while Joenja® (leniolisib) reached US$15.1 million (up 35%) as paid therapy patients grew.
Operating profit rose to US$15.8 million (up 285%), and net profit was US$7.5 million versus a loss last year. Cash flow from operations was US$32.0 million, lifting cash, restricted cash and marketable securities to US$168.9 million at quarter‑end. The company raised 2025 revenue guidance to US$365–US$375 million.
Regulatory momentum continued as the FDA granted Priority Review for the leniolisib sNDA in children aged 4–11 with APDS, with a January 31, 2026 PDUFA date. Pharming will withdraw RUCONEST® from non‑U.S. markets (US$1.1 million in Q3 revenue) to focus resources, and expects a one‑time ~US$7 million restructuring charge in Q4 tied to a 20% reduction in non‑commercial and non‑medical headcount. Leverne Marsh will become CCO on January 1, 2026.
Pharming Group N.V. furnished a press release noting that 12 abstracts were accepted for presentation at the 2025 ACAAI Annual Scientific Meeting in Orlando on November 6–10. The program includes five posters with new clinical, economic, and comparative data on RUCONEST for on-demand treatment of hereditary angioedema, and seven posters with real‑world effectiveness and pediatric data on Joenja (leniolisib) in APDS, plus caregiver and burden-of-illness insights.
Topics span indirect treatment comparisons, cost‑effectiveness, time‑to‑event endpoint analyses, patient‑reported outcomes, adherence, healthcare utilization, and registry characterization. ePosters will be accessible to registered attendees beginning November 6 at 08:00 EST via ACAAI’s website.
Pharming Group N.V. has begun an organizational restructuring designed to accelerate growth while cutting overhead. The company is redesigning its structure and reducing non-commercial and non-medical headcount by 20%, mainly at its Netherlands headquarters, as part of a previously announced general and administrative (G&A) expense reduction plan.
Pharming states it remains on track to lower total G&A expenses by 15%, or about US$10 million annually. The company expects one-time restructuring charges of roughly $7 million to be recorded in the fourth quarter of 2025 in connection with the headcount reduction.
Pharming Group announced the FDA has accepted its supplemental NDA seeking approval of leniolisib (Joenja) for children aged 4–11 with activated phosphoinositide 3-kinase delta syndrome (APDS). The application received Priority Review with a PDUFA target action date of January 31, 2026. The sNDA is supported by positive data from a multinational, single-arm Phase III study in 4–11-year-olds showing, over 12 weeks, reductions in lymphadenopathy and increases in naïve B cells, indicating correction of the underlying immune defect; the submission also included safety data from 8 months of treatment. There are no approved treatments globally for children under 12 with APDS. Leniolisib is already approved in the U.S. for patients aged 12 and older (March 2023).
Pharming Group N.V. filed a Form 6-K to report that it has been promoted from the Euronext AScX (Small Cap) to the Euronext AMX (MidCap) index, effective September 22, 2025. The AMX index includes 25 companies selected by Euronext Amsterdam based on free-float market capitalization and liquidity, and this move marks Pharming’s return to the AMX.
The company describes this promotion as a reflection of its strong financial and pipeline growth momentum and expects AMX inclusion to increase its visibility and attractiveness to investors. Management reiterates its focus on executing commercial and pipeline catalysts as it aims to develop further as a global rare disease company.